Age-Related Macular Degeneration - Global Strategic Business Report

The global market for Age-Related Macular Degeneration was estimated at US$10.9 Billion in 2024 and is projected to reach US$16.4 Billion by 2030, growing at a CAGR of 7.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Age-Related Macular Degeneration market.

Global Age-Related Macular Degeneration Market - Key Trends & Drivers Summarized

Why Is the Prevalence of Age-Related Macular Degeneration Increasing Globally?

The rising global prevalence of age-related macular degeneration is driven by the rapidly aging population and increasing life expectancy. As the proportion of elderly individuals grows, the incidence of AMD, a leading cause of irreversible vision loss in older adults, continues to escalate. Lifestyle factors such as unhealthy diets, smoking, and prolonged exposure to blue light from digital screens have also contributed to the rising burden of AMD worldwide. Moreover, the growing awareness about eye health and the increasing frequency of routine eye examinations are leading to earlier diagnosis and treatment of AMD, thereby expanding the market for therapeutic interventions. Healthcare organizations and governments are intensifying efforts to educate the public about the importance of early detection and preventive measures, which is positively impacting the demand for AMD-related diagnostics and treatments.

How Are Advances in Treatment Options Shaping the AMD Market?

Innovative treatment approaches and the introduction of novel therapies are significantly transforming the AMD market landscape. Anti-vascular endothelial growth factor (anti-VEGF) injections continue to dominate the treatment paradigm for wet AMD, offering improved vision outcomes and slowing disease progression. However, recent advancements in gene therapy, stem cell research, and sustained drug delivery systems are offering new hope for patients with both wet and dry AMD. Emerging therapies, such as complement inhibitors and oral treatments targeting inflammation and oxidative stress, are gaining traction as potential disease-modifying solutions. Additionally, the development of longer-acting biologics and implantable drug delivery devices is improving patient compliance by reducing the frequency of injections. As pharmaceutical companies continue to invest heavily in R&D, the pipeline for AMD treatments remains robust, promising a shift towards more personalized and effective therapeutic options.

What Are the Key Market Challenges and Opportunities?

Despite the significant progress in AMD treatment, challenges such as high treatment costs, limited access to advanced therapies, and the absence of a definitive cure for dry AMD continue to pose hurdles to market growth. The high price of anti-VEGF injections, coupled with the need for frequent administration, places a financial burden on patients and healthcare systems, particularly in low- and middle-income countries. Additionally, the lack of effective therapies for geographic atrophy, an advanced form of dry AMD, remains an unmet need, driving researchers to explore novel therapeutic targets. However, these challenges present opportunities for innovation, with market players focusing on cost-effective solutions and patient-friendly drug delivery mechanisms. The increasing adoption of teleophthalmology and artificial intelligence-based screening tools is also opening new avenues for early detection and remote monitoring, enhancing accessibility and patient outcomes.

What Are the Key Factors Driving Growth in the AMD Market?

The growth in the Age-Related Macular Degeneration market is driven by several factors, including the rising aging population, increasing adoption of advanced treatment modalities, and the expanding availability of healthcare services globally. The growing focus on precision medicine and biomarker-driven therapies is leading to more targeted and effective treatments, further boosting market growth. Additionally, the increasing prevalence of lifestyle-related risk factors, such as diabetes and hypertension, which contribute to AMD progression, is fueling the demand for early interventions and preventive measures. The expansion of healthcare infrastructure, particularly in emerging economies, and the growing investment by pharmaceutical companies in ophthalmology research are also contributing to market growth. Furthermore, the introduction of reimbursement policies and patient assistance programs is making AMD treatments more accessible, driving higher treatment adoption rates across different demographics.

Report Scope

The report analyzes the Age-Related Macular Degeneration market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Product (Eylea Age-related Macular Degeneration, Lucentis Age-related Macular Degeneration, Beovu Age-related Macular Degeneration, Other Products); Disease (Wet Age-related Macular Degeneration, Dry Age-related Macular Degeneration); Distribution Channel (Hospital Pharmacy Distribution Channels, Specialty Pharmacy Distribution Channels, Online Pharmacy Distribution Channels)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Eylea Age-related Macular Degeneration segment, which is expected to reach US$7.9 Billion by 2030 with a CAGR of a 8.1%. The Lucentis Age-related Macular Degeneration segment is also set to grow at 6.9% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $3.0 Billion in 2024, and China, forecasted to grow at an impressive 11.2% CAGR to reach $3.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Age-Related Macular Degeneration Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Age-Related Macular Degeneration Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Age-Related Macular Degeneration Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Adverum Biotechnologies Inc., Alkeus Pharmaceuticals Inc., Apellis Pharmaceuticals, Inc., Bausch & Lomb, Inc., Bayer AG and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 34 Featured):

• Adverum Biotechnologies Inc.
• Alkeus Pharmaceuticals Inc.
• Apellis Pharmaceuticals, Inc.
• Bausch & Lomb, Inc.
• Bayer AG
• F. Hoffmann-La Roche AG
• Lupin Ltd.
• Novartis AG
• Outlook Therapeutics, Inc.
• Opthea Limited
• Regeneron Pharmaceuticals Inc.
• Ribomic Inc.
• Xbrane Biopharma AB

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry